Autophagy in tumorigenesis and cancer therapy

doi:10.3760/cma.j.issn.1673-422X.2018.12.009

Abstract

Abstract: Autophagy is a crucial physiological process for cellular selfrenewing and homeostasis, which plays a dual role in both tumorigenesis and antitumor treatment. It plays an antineoplastic role by maintaining genomic stability, as well as a protective role in tumorgenesis and progression. Autophagy improves the effectiveness of antitumor therapy, meanwhile, it involves in resistance of tumor cells to chemotherapy and irradiation. Using relevant autophagy regulators in different backgrounds is expected to become a new strategy for improving sensitivity of tumor cells to antitumor treatment.

Key words: Autophagy, Neoplasms, Drug therapy, Radiotherapy, Targeted therapy

Wang Xin, Song Haiping, Wang Ye, Sun Hongquan, Ma Xuezhen. Autophagy in tumorigenesis and cancer therapy[J]. Journal of International Oncology, 2018, 45(12): 743-746.

References

［1］ Giampieri F, Afrin S, ForbesHernandez TY, et al. Autophagy in human health and disease: novel therapeutic opportunities［J］. Antioxid Redox Signal, 2018, In press. DOI: 10.1089/ars.2017.7234. ［2］ Di Fazio P, Matrood S. Targeting autophagy in liver cancer［J］. Transl Gastroenterol Hepatol, 2018, 3: 39. DOI: 10.21037/tgh.2018.06.09. ［3］ Vigen RA, Kodama Y, Viset T, et al. Immunohistochemical evidence for an impairment of autophagy in tumorigenesis of gastric carcinoids and adenocarcinomas in rodent models and patients［J］. Histol Histopathol, 2013, 28(4): 531542. DOI: 10.14670/HH28.531. ［4］ Cai J, Li R, Xu X, et al. CK1α suppresses lung tumour growth by stabilizing PTEN and inducing autophagy［J］. Nat Cell Biol, 2018, 20(4): 465478. DOI: 10.1038/s4155601800658. ［5］ Zhai H, Fesler A, Ba Y, et al. Inhibition of colorectal cancer stem cell survival and invasive potential by hsamiR1405p mediated suppression of Smad2 and autophagy［J］. Oncotarget, 2015, 6(23): 1973519746. DOI: 10.18632/oncotarget.3771. ［6］ Han H, Li J, Feng X, et al. Autophagyrelated genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells［J］. Oncotarget, 2017, 8(32): 5335253365. DOI: 10.18632/oncotarget.18410. ［7］ Chiu HW, Yeh YL, Wang YC, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo［J］. PLoS One, 2013, 8(10): e76340. DOI: 10.1371/journal.pone.0076340. ［8］ Palumbo S, Pirtoli L, Tini P, et al. Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments［J］. J Cell Biochem, 2012, 113(7): 23082318. DOI: 10.1002/jcb.24102. ［9］ Nguyen TL, Nokin MJ, Egorov M, et al. mTOR inhibition via displacement of phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells［J］. Cancer Res, 2018, 78(18): 53845397. DOI: 10.1158/00085472.CAN180232. ［10］ Sulaiman A, McGarry S, Lam KM, et al. Coinhibition of mTORC1, HDAC and ESR1α retards the growth of triplenegative breast cancer and suppresses cancer stem cells［J］. Cell Death Dis, 2018, 9(8): 815. DOI: 10.1038/s4141901808117. ［11］ Park JH, Lee YR, So HS, et al. The role of autophagy induced by pemetrexed in lung adenocarcinoma cells［J］. Oncol Rep, 2014, 31(5): 23652370. DOI: 10.3892/or.2014.3071. ［12］ Li LQ, Pan D, Zhang SW, et al. Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway［J］. Eur Rev Med Pharmacol Sci, 2018, 22(11): 34023407. DOI: 10.26355/eurrev_201806_15162. ［13］ Li H, Jin X, Chen B, et al. Autophagyregulating microRNAs: potential targets for improving radiotherapy［J］. J Cancer Res Clin Oncol, 2018, 144(9): 16231634. DOI: 10.1007/s0043201826758. ［14］ Jin X, Liu Y, Ye F, et al. Role of autophagy in high linear energy transfer radiationinduced cytotoxicity to tumor cells［J］. Cancer Sci, 2014, 105(7): 770778. DOI: 10.1111/cas.12422. ［15］ Koukourakis MI, Kalamida D, Mitrakas A, et al. Intensified autophagy compromises the efficacy of radiotherapy against prostate cancer［J］. Biochem Biophys Res Commun, 2015, 461(2): 268274. DOI: 10.1016/j.bbrc.2015.04.014. ［16］ Mo N, Lu YK, Xie WM, et al. Inhibition of autophagy enhances the radiosensitivity of nasopharyngeal carcinoma by reducing Rad51 expression［J］. Oncol Rep, 2014, 32(5): 19051912. DOI: 10.3892/or.2014.3427. ［17］ Chaachouay H, Ohneseit P, Toulany M, et al. Autophagy contributes to resistance of tumor cells to ionizing radiation［J］. Radiother Oncol, 2011, 99(3): 287292. DOI: 10.1016/j.radonc.2011.06.002. ［18］ Li H, Jin X, Chen B, et al. Autophagyregulating micrornas: potential targets for improving radiotherapy［J］. J Cancer Res Clin Oncol, 2018, 144(9): 16231634. DOI: 10.1007/s0043201826758. ［19］ Wang P, Zhang J, Zhang L, et al. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells［J］. Gastroenterology, 2013, 145(5): 11331143. e12. DOI: 10.1053/j.gastro.2013.07.048. ［20］ Zhou ZR, Yang ZZ, Wang SJ, et al. The Chk1 inhibitor MK8776 increases the radiosensitivity of human triplenegative breast cancer by inhibiting autophagy［J］. Acta Pharmacol Sin, 2017, 38(4): 513523. DOI: 10.1038/aps.2016.136. ［21］ Zheng L, Zhang Y, Liu Y, et al. MiR106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer［J］. J Transl Med, 2015, 13: 252. DOI: 10.1186/s129670150592z. ［22］ Hu JL, He GY, Lan XL, et al. Inhibition of ATG12mediated autophagy by miR214 enhances radiosensitivity in colorectal cancer［J］. Oncogenesis, 2018, 7(2): 16. DOI: 10.1038/s4138901800288. ［23］张其程, 徐克. 自噬在EGFRTKI类肿瘤靶向药物对肺癌的治疗和耐药中作用的研究进展［J］. 中国肺癌杂志, 2016, 19(9): 607614. DOI: 10.3779/j.issn.10093419.2016.09.09. ［24］ Wei Y, Zou Z, Becker N, et al. EGFRmediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance［J］. Cell, 2013, 154(6): 12691284. DOI: 10.1016/j.cell.2013.08.015. ［25］ Han W, Pan H, Chen Y, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells［J］. PLoS One, 2011, 6(6): e18691. DOI: 10.1371/journal.pone.0018691. ［26］ Lee JG, Wu R. Combination erlotinibcisplatin and Atg3mediated autophagy in erlotinib resistant lung cancer［J］. PLoS One, 2012, 7(10): e48532. DOI: 10.1371/journal.pone.0048532. ［27］ Huang Y, Chen Y, Mei Q, et al. Combined inhibition of the EGFR and mTOR pathways in EGFR wildtype nonsmall cell lung cancer cell lines with different genetic backgrounds［J］. Oncol Rep, 2013, 29(6): 24862492. DOI: 10.3892/or.2013.2357. ［28］ Xu Z, Hang J, Hu J, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells［J］. J BUON, 2014, 19(2): 466473.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[13]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[14]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[15]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.